These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26577335)

  • 81. Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab.
    MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2017 May; 139(5):1680-1682.e10. PubMed ID: 28259446
    [No Abstract]   [Full Text] [Related]  

  • 82. How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria.
    Kaplan AP; Joseph K; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(4):648. PubMed ID: 26164583
    [No Abstract]   [Full Text] [Related]  

  • 83. [IgE and Anti-IgE in Asthma: A Chequered History].
    Lommatzsch M; Geißler K; Bergmann KC; Virchow JC
    Pneumologie; 2017 Jun; 71(6):398-405. PubMed ID: 28651294
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Anti-IgE for chronic urticaria - are children little adults after all?
    Ulrich W
    Pediatr Allergy Immunol; 2015 Sep; 26(6):488-9. PubMed ID: 26358686
    [No Abstract]   [Full Text] [Related]  

  • 85. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.
    Bourgoin-Heck M; Amat F; Trouvé C; Bernard A; Magny JP; Lambert N; Just J
    Pediatr Allergy Immunol; 2018 Feb; 29(1):90-93. PubMed ID: 28981968
    [No Abstract]   [Full Text] [Related]  

  • 86. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
    Forbush JT; Banks TA
    Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
    [No Abstract]   [Full Text] [Related]  

  • 87. Effects of omalizumab on T lymphocyte function in inner-city children with asthma.
    Gruchalla RS; Sampson HA; Liu AH; Shreffler W; Wallace PK; Togias A; David G; Calatroni A; LeBeau P;
    Pediatr Allergy Immunol; 2016 May; 27(3):328-31. PubMed ID: 26573086
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The use of biologic therapies for the management of pediatric asthma.
    Lovinsky-Desir S
    Pediatr Pulmonol; 2020 Mar; 55(3):803-808. PubMed ID: 31880870
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Omalizumab in "non-IgE-mediated" diseases.
    Chinthrajah RS; Galli SJ
    J Allergy Clin Immunol; 2021 Apr; 147(4):1207-1208. PubMed ID: 33160970
    [No Abstract]   [Full Text] [Related]  

  • 90. Th1-related disease development during omalizumab treatment: Two cases with severe asthma.
    Hayashi H; Fukutomi Y; Mitsui C; Watai K; Tomita Y; Kamide Y; Sekiya K; Tsuburai T; Horita A; Saito I; Hasegawa Y; Taniguchi M
    Allergol Int; 2018 Jul; 67(3):405-407. PubMed ID: 29191372
    [No Abstract]   [Full Text] [Related]  

  • 91. Severe and Difficult-to-Treat Asthma in Adults.
    Israel E; Reddel HK
    N Engl J Med; 2017 Sep; 377(10):965-976. PubMed ID: 28877019
    [No Abstract]   [Full Text] [Related]  

  • 92. Control of asthma by omalizumab: the role of CD4
    Amat F; Tallon P; Foray AP; Michaud B; Lambert N; Saint-Pierre P; Chatenoud L; Just J
    Clin Exp Allergy; 2016 Dec; 46(12):1614-1616. PubMed ID: 27770456
    [No Abstract]   [Full Text] [Related]  

  • 93. Omalizumab: a treatment for severe asthma in real life?
    Briquet A; Chanez P
    Rev Port Pneumol (2006); 2015; 21(3):111-2. PubMed ID: 25943448
    [No Abstract]   [Full Text] [Related]  

  • 94. Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab.
    Draikiwicz S; Oppenheimer J
    Chest; 2017 Feb; 151(2):249-251. PubMed ID: 28183482
    [No Abstract]   [Full Text] [Related]  

  • 95. The impact of socioeconomic risk factors and mental health on asthma.
    Le TP; Sutherlin TK; Teverbaugh LA; Gleason MM; Carlson JC
    Ann Allergy Asthma Immunol; 2021 May; 126(5):453-457. PubMed ID: 33610758
    [No Abstract]   [Full Text] [Related]  

  • 96. Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma.
    Gouder C; Asciak R; Montefort S
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):513-514. PubMed ID: 28283278
    [No Abstract]   [Full Text] [Related]  

  • 97. Understanding the response to asthma biological therapy.
    Roberts G
    Clin Exp Allergy; 2020 Sep; 50(9):992-993. PubMed ID: 32902035
    [No Abstract]   [Full Text] [Related]  

  • 98. Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal.
    D de Sousa M; Ferreira C; Arrobas A
    Rev Port Pneumol (2006); 2017; 23(2):108-109. PubMed ID: 28209342
    [No Abstract]   [Full Text] [Related]  

  • 99. Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation.
    Caminati M; Gatti D; Dama A; Lorenzetti L; Senna G
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):460-462. PubMed ID: 28941707
    [No Abstract]   [Full Text] [Related]  

  • 100. Cluster Subanalysis of Patients With Severe Asthma Who Responded to Omalizumab.
    Dávila I; Campo P; Cimbollek S; Almonacid Sánchez C; Quirce S; Moreira A; Ramirez A; Soto Campos G
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):213-215. PubMed ID: 34581281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.